Alder BioPharmaceuticals: Lundbeck Acquires US Migraine Treatment Firm
Danish drugmaker Lundbeck is to acquire the US migraine treatment company Alder BioPharmaceuticals (Bothell, WA) in a transaction valued at up to $1.95 billion. Alder is developing eptinezumab an investigational monoclonal antibody (mAb) that is administered as a quarterly 30-minute IV inf
Read full article »
Alder is a biopharmaceutical company that focuses on developing novel therapeutic antibodies for the treatment of migraine.
Read more